2/2
08:05 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
1/30
06:40 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/30
04:30 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/30
09:25 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $40.00 price target on the stock.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $40.00 price target on the stock.
1/30
08:02 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
1/30
07:36 am
smmt
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) [Seeking Alpha]
Medium
Report
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) [Seeking Alpha]
1/29
07:30 am
smmt
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
Medium
Report
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
1/29
12:23 am
smmt
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" [Yahoo! Finance]
Low
Report
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026" [Yahoo! Finance]
1/28
07:18 am
smmt
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive [Yahoo! Finance]
Low
Report
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive [Yahoo! Finance]
1/24
05:10 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/14
10:00 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
1/14
08:42 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/13
01:36 pm
smmt
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
Low
Report
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
1/13
12:37 am
smmt
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
1/12
12:16 pm
smmt
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]
Low
Report
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]
1/12
06:31 am
smmt
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) [Yahoo! Finance]
High
Report
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) [Yahoo! Finance]
1/12
06:17 am
smmt
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC [Yahoo! Finance]
High
Report
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC [Yahoo! Finance]
1/12
06:15 am
smmt
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
High
Report
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
1/12
06:00 am
smmt
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
High
Report
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
1/9
08:16 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/6
05:48 pm
smmt
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib [Yahoo! Finance]
Low
Report
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib [Yahoo! Finance]
1/6
07:30 am
smmt
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/2
09:22 am
smmt
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst [Yahoo! Finance]
Low
Report
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst [Yahoo! Finance]
12/17
09:12 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
12/17
05:10 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was given a new $18.00 price target on by analysts at Summit Redstone.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) was given a new $18.00 price target on by analysts at Summit Redstone.